NCT00101036: Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery |
|
|
| Completed | 2 | 57 | US | lapatinib ditosylate, GSK572016, GW-572016, GW2016, Lapatinib, Tykerb, laboratory biomarker analysis | National Cancer Institute (NCI) | Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer | 01/09 | 01/09 | | |
NCT00107536: Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer |
|
|
| Completed | 2 | 26 | US | lapatinib ditosylate, GSK572016, GW-572016, GW2016, Lapatinib, Tykerb, laboratory biomarker analysis | National Cancer Institute (NCI) | Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer | 05/09 | 05/09 | | |
